Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harmony Biosciences excels in Q4, eyes growth in new markets

Harmony Biosciences delivered strong financial results, emphasizing growth strategies and confidence in WAKIX's revenue potential. The company is well-positioned with a focus on new prescribers, lifecycle management, and potential business development opportunities.

Harmony Biosciences excels in Q1, eyes expansion and shareholder value

Harmony Biosciences' Q1 2023 showcased strong financial performance, significant patient growth on WAKIX, and strategic plans for portfolio expansion.
The company's commercial model evolution and confidence in WAKIX's growth potential position it well for future opportunities.
Addressing challenges like patient attrition rates and regulatory concerns while exploring new business development avenues highlight Harmony's proactive approach.
With a focus on maximizing shareholder value and sustaining growth post-WAKIX, Harmony Biosciences remains poised for continued success.

Harmony Biosciences excels in Q2, eyes growth amid challenges

Harmony Biosciences delivered a strong Q2 performance, showcasing growth in net sales and patient numbers for WAKIX. The company's financial strength, strategic capital deployment, and focus on clinical development programs position it well for future growth. While facing challenges like patent disputes and market dynamics, Harmony Biosciences remains confident in its business fundamentals and growth potential.

Harmony Biosciences Achieves Record Revenue in Q3 2023

Harmony Biosciences delivered a stellar performance in Q3 2023, marked by record revenue, strong profitability, and strategic acquisitions, positioning the company for future growth.
While facing challenges in patent litigation and regulatory approvals, the company's focus on innovation, commercial excellence, and financial strength underpin its resilience.
With a clear market opportunity in narcolepsy, ongoing pipeline advancements, and a commitment to shareholder value, Harmony Biosciences remains well-positioned for long-term success.

Harmony Biosciences reports robust earnings, eyes strategic growth in 2024

Harmony Biosciences' strong financial performance, strategic acquisitions, and clinical advancements position the company for continued growth and market success.
Balancing revenue growth, pricing strategies, and clinical developments will be key focus areas for the company in navigating market challenges and opportunities.
With a focus on innovation, regulatory relationships, and financial prudence, Harmony Biosciences aims to drive sustainable growth and shareholder value in 2024.
The company's proactive approach to business development, share repurchases, and revenue guidance reflects a strategic and forward-thinking mindset for future success.

Harmony Biosciences excels in Q1, poised for long-term growth

Harmony Biosciences delivered strong financial performance in Q1, driven by WAKIX's growth and strategic acquisitions, positioning the company for continued success.
Despite operational challenges and market competition, the company's focus on innovation, rare disease treatments, and CNS franchises presents significant growth opportunities.
With a robust financial position, disciplined capital deployment, and a promising pipeline, Harmony Biosciences is poised for long-term value creation and revenue growth.
FDA recognition of unmet medical needs, positive clinical developments, and strong IP protection underscore the company's potential for market leadership and patient impact.

Harmony Biosciences reports robust Q2 performance and growth opportunities

Harmony Biosciences delivered a strong Q2 performance with revenue growth, FDA approvals, and pipeline advancements. The company's financial strength, upheld patents, and strategic growth focus position it well for future success despite some challenges.

Harmony Biosciences excels in Q3, eyes growth amid legal challenges

Harmony Biosciences demonstrated strong financial performance and pipeline progress in Q3 2024, positioning itself for continued growth.
While facing IP litigation and challenges in rare orphan categories, the company's focus on innovation and market positioning presents opportunities for future success.
Maintaining financial strength, pursuing pipeline advancements, and navigating legal hurdles will be key for Harmony Biosciences' sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Excelerate Energy and biotech leaders Harmony and Immunocore are among the top IPO stocks to buy and watch in the stock market rally. The post IPO Stock Of The Week Roundup: Excelerate, Harmony Biosciences, Immunocore appeared first on Investor's Business Daily.

IPO Stock Of The Week Roundup: Excelerate, Harmony Biosciences, Immunocore

Catalyst Pharmaceuticals

Genmab - ADR

Neurocrine Biosciences

Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.

Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases

Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Harmony Biosciences (HRMY) Stock Might be a Great Pick

PLYMOUTH MEETING, Pa. , Nov. 9, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.

HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 34th ANNUAL HEALTHCARE CONFERENCE

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Luis Sanay - Head-Investor Relations John Jacobs - President & Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Jeffrey Dayno - Chief Medical Officer Sandip Kapadia - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer David Amsellem - Piper Sandler Charles Duncan - Cantor Fitzgerald Corinne Jenkins - Goldman Sachs Chris Howerton - Jefferies Graig Suvannavejh - Mizuho Securities Operator Good morning. My name is Gretchin, and I will be your conference operator today.

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2022 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates

WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021

Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates

PLYMOUTH MEETING, Pa. , Nov. 1, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced initial topline results from its Phase 2 proof-of-concept study in patients with Prader-Willi syndrome (PWS), which showed a positive signal on improvement in the primary outcome related to excessive daytime sleepiness (EDS).

HARMONY BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH PRADER-WILLI SYNDROME

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Harmony Biosciences Holdings, Inc. (HRMY) to Report a Decline in Earnings: What to Look Out for

IPO Stock Of The Week Harmony Biosciences is holding up well during the stock market correction. The post IPO Stock Of The Week: Harmony Biosciences Outperforms In A Tough Market appeared first on Investor's Business Daily.

IPO Stock Of The Week: Harmony Biosciences Outperforms In A Tough Market

PLYMOUTH MEETING, Pa. , Oct. 18, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2022 financial results on Tuesday, November 1, 2022, before the open of the U.S. financial markets.

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022

Harmony Biosciences has seen a strong performance of its WAKIX drug since it went public in 2020. This run up made that shares have done quite alright, vastly outperforming most IPOs of the time.

Harmony Biosciences: In Harmony

PLYMOUTH MEETING, Pa. , Sept. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart and Progress at the Heart award programs.

HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Luis Sanay - Head, IR John Jacobs - President and CEO Jeffrey Dierks - Chief Commercial Officer Jeffrey Dayno - Chief Medical Officer Sandip Kapadia - CFO Conference Call Participants Chris Howerton - Jefferies Danielle Brill - Raymond James Charles Duncan - Cantor Fitzgerald Graig Suvannavejh - Goldman Sachs Corinne Jenkins - Goldman Sachs David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Operator Good morning, my name is Katie and I'll be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences Second Quarter 2022 Financial Update Conference Call.

Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q2 2022 Results - Earnings Call Transcript

Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged. The post Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat appeared first on Investor's Business Daily.

Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat

WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021

Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates

Aris Water Solution

Driven Brands Holdings

Aris Water Solutions, Driven Brands and Harmony are among the top IPO stocks to watch in today's stock market rally. The post IPO Stock Roundup: Aris Eyes Buy Point While Harmony's Big Gains Fade appeared first on Investor's Business Daily.

IPO Stock Roundup: Aris Eyes Buy Point While Harmony's Big Gains Fade

PLYMOUTH MEETING, Pa. , July 19, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's second quarter 2022 financial results on Tuesday, August 2, 2022.

HARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS

Can turning one product into a portfolio of products result in revenue magic?

Investors Are Paying Attention to This Pharma That Is Gaining Speed

Biogen

CinCor Pharma

CRISPR Therapeutics

Emergent BioSolutions

Global Blood Therapeutics

Vigil Neuroscience

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on InvestorPlace.

7 No-Brainer Biotech Stocks to Add to Your Buy List

PLYMOUTH MEETING, Pa. , June 6, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced results of a post-hoc analysis from the pivotal data evaluating the clinical impact of WAKIX® (pitolisant) on the reduction of excessive daytime sleepiness (EDS) and cataplexy in adults with a high burden of narcolepsy symptoms.

HARMONY BIOSCIENCES PRESENTS POST-HOC ANALYSIS OF WAKIX® (PITOLISANT) PIVOTAL DATA IN ADULTS WITH HIGH BURDEN OF NARCOLEPSY SYMPTOMS

Harmony has done very well monetizing their first asset. They have to start planning for the future.

Harmony Biosciences: Steady Revenue Generator Looking For A Future

NEW YORK , May 5, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY). If you are a shareholder of Harmony Biosciences Holdings, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: http://pjlfirm.com/harmony-biosciences-holdings-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Harmony Biosciences Holdings, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Luis Sanay - Head, IR John C. Jacobs - President and CEO Jeffrey Dierks - Chief Commercial Officer Jeffrey M.

Harmony Biosciences Holdings, Inc. (HRMY) CEO John Jacobs on Q1 2022 Results - Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Harmony Biosciences Holdings Stock (HRMY)